Peritoneal dialysis in the 21st century: An analysis of current problems and future developments

Journal of the American Society of Nephrology

Volumn 13, Issue SUPPL. 1, 2001, Pages

  Gokal, R ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; BICARBONATE; OSMOTIC AGENT; PERITONEAL DIALYSIS FLUID;

AUTOMATION; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; FUTUROLOGY; GENE THERAPY; HUMAN; INFECTIOUS COMPLICATION; KIDNEY FAILURE; MEDICAL RESEARCH; OUTCOMES RESEARCH; PERITONEAL DIALYSIS; PERITONITIS; PRIORITY JOURNAL; REVIEW;

EID: 0035651809     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (153)

1. Why are reported relative mortality risks for CAPD and HD so variable?
2. A comparison of mortality between patients treated with hemodialysis and peritoneal dialysis
3. Hemodialysis versus peritoneal dialysis: A comparison of adjusted mortality rates
4. Comparative mortality of hemodialysis and peritoneal dialysis in Canada
5. Excerpts from the USRDS 2000 Annual Data Report: Atlas of end-stage renal disease in the United States
6. Mortality risks of peritoneal dialysis and hemodialysis
7. Trends in mortality on peritoneal dialysis: Canada, 1981-1997
8. Outcome with peritoneal dialysis compared to haemodialysis
9. What really happens to people on long-term peritoneal dialysis?
10. Is long-term technique survival on CAPD possible?
11. Peritoneal dialysis as long-term treatment: Comparison of technique survival between Asian and Western populations
12. National comparisons: Optimal peritoneal dialysis outcomes among Japanese patients
13. Technique failure in peritoneal dialysis and its impact on patient survival
14. The influence of CAPD connection technique on peritonitis rate and technique survival
15. Twin vs single-bag disconnect systems: Infection rates and cost of CAPD
16. Infecting organisms in CAPD patients on the Y-set
17. Controlled trial of a Y-set dialysis delivery system to prevent peritonitis in patients receiving CAPD
18. Staphylococcus aureus nasal carriage and infection in patients on continuous ambulatory peritonitis
19. Staphylococcus aureus peritonitis is associated with Staphylococcus aureus nasal carriage in peritoneal dialysis patients
20. A randomised trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: Mupirocin calcium ointment 2% applied to exit site versus cyclic oral rifampin
21. Nasal mupirocin prevents Staphylococcus aureus exit site infection during peritoneal dialysis
22. Decrease in Staphylococcus aureus exit-site infections and peritonitis in CAPD patients by local application of mupirocin ointment at the catheter exit site
23. Peritoneal catheters and exit site practices towards optimal peritoneal access, 1998: Update
24. The definition of a novel portable/wearable equilibrium dialysis technique
25. A quantitative approach to the CAPD prescription
26. Clinical practice guidelines for peritoneal dialysis adequacy
27. Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients
28. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: Association with clinical outcomes
29. Are there limits for CAPD? Adequacy and nutritional considerations
30. Adequacy, nutrition and cardiovascular outcome in peritoneal dialysis
31. Optimal peritoneal dialysis for patients from Hong Kong
32. Peritoneal membrane morphology and function
33. The physiology of peritoneal solute transport and ultrafiltration
34. Demonstration of aquaporin chip in peritoneal tissue of uremic and CAPD patients
35. Peritoneal lymphatics
36. Peritoneal transport: Clinical implications
37. Peritoneal membrane biology
38. Reduplicated basal lamina of small venules and mesothelium of human peritoneal membrane
39. New concepts in molecular biology and ultrastructural pathology of the peritoneum: Their significance for peritoneal dialysis
40. Peritoneal vascular changes in CAPD: An in vivo model for the study of diabetic microangiopathy
41. Long-term effects of peritoneal dialysis on peritoneal morphology
42. Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure
43. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD
44. Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis
45. Sclerosing peritonitis: The experience in Australia
46. National comparisons: Optimal peritoneal dialysis outcomes among Japanese patients
47. Analysis of ultrafiltration failure in peritoneal dialysis patients by means of standard peritoneal permeability analysis
48. What really happens to people on long-term peritoneal dialysis?
49. Longitudinal changes in peritoneal kinetics: The effect of peritoneal dialysis and peritonitis
50. Functional longevity of the human peritoneum: How long is continuous peritoneal dialysis possible? Results of a prospective medium-term study
51. Does impaired transcellular water transport contribute to net ultrafiltration failure during CAPD?
52. Glucose and insulin metabolism in uremia
53. Sequential changes in serum lipids and their sub-fractions in patients receiving CAPD
54. Conventional and newer peritoneal dialysis solutions
55. Biocompatibility studies on peritoneal cells
56. Bicarbonate/lactate and bicarbonate buffered peritoneal dialysis fluids improve ex vivo peritoneal macrophage TNF alpha secretion
57. Effect of lactate buffered peritoneal dialysis fluid on human peritoneal mesothelial cells, interleukin-6 and prostaglandin synthesis
58. Improved cell function in pyruvate-buffered peritoneal dialysis fluids is related to specific antagonism of the polyol pathway
59. Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis
60. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis
61. Accumulation of advanced glycation end products in the vasculature of CAPD patients with low ultra-filtration
62. Immunohistochemical study of human advanced glycosylation end products (AGE) in chronic renal failure
63. The pathogenesis and consequences of AGE formation in uraemia and its treatment
64. CAPD viability: A long-term comparison with hemodialysis
65. Nursing home dialysis: Can we meet the challenge?
66. Incidence, prevalence and outcomes of ESRD patients placed in nursing homes
67. Ten years' experience with CAPD in a nursing home setting
68. Malnutrition, cardiac disease and mortality - An integrated point of view
69. Strong association between malnutrition, inflammation and atherosclerosis in chronic renal failure
70. Arterial stiffening and vascular calcification in end-stage renal disease
71. Plasma and Lp(a)-associated PAF-acetyl-hydrolase activity in uremic patients undergoing different dialysis procedures
72. Elevated serum levels of soluble adhesion molecules predict death in pre-dialysis patients: Association with malnutrition, inflammation and cardiovascular disease
73. Nutritional assessment of continuous ambulatory peritoneal dialysis patients: An international study
74. Acute phase protein and peritoneal dialysate albumin loss are primary determinants of serum albumin in peritoneal dialysis patients
75. Does a high peritoneal transport rate reflect a state of chronic inflammation?
76. Impact of nutritional status on serum lipoprotein (a) concentration in patients undergoing continuous ambulatory peritoneal dialysis
77. Histological, radiological, and biochemical features of the adynamic bone lesion in CAPD patients
78. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease
79. Association of serum phosphorus and calcium X phosphate product with mortality risk in chronic hemodialysis patients: A national study
80. Coronary artery calcification in young adults with end stage renal disease who are undergoing dialysis
81. Urea kinetics and when to commence dialysis
82. What is the level of GFR in the US ESRD population?
83. Residual renal function and nutritional status at the start of chronic dialysis treatment
84. Spontaneous dietary protein intake during progression of chronic renal failure
85. Nutritional status of patients with different levels of chronic renal insufficiency
86. How much peritoneal dialysis is required for maintaining a good nutritional state?
87. An evidence based approach to earlier initiation of dialysis
88. Death risk in CAPD patients. The predictive value of the initial clinical and laboratory variables
89. Impact of the initial levels of laboratory variables on the survival in chronic dialysis patients
90. Timely initiation of dialysis: A urea kinetic approach
91. Towards targets for initiation of chronic dialysis
92. Early initiation of chronic dialysis: Role of incremental dialysis
93. Incremental initiation of dialysis: One center's experience over a two-year period
94. Continuous adaptation of the dialysis prescription maintains adequate Kprt/V in CAPD patients
95. Preliminary evaluation of incremental peritoneal dialysis in 25 patients
96. Early start to peritoneal dialysis: To start or not to start?
97. The role of peritoneal dialysis as the first-line renal replacement modality
98. What is the place of peritoneal dialysis in the integrated treatment of renal failure
99. Evaluation of an integrative care for ESRD patients
100. Predictors of loss of renal function among new dialysis patients
101. Hepatitis C virus infection in dialysis and renal transplantation
102. Mode of dialysis therapy and mortality in end stage renal disease
103. Dialysis modality and delayed graft function after cadaveric renal transplantation
104. Peritoneal dialysis favourably influences recovery of renal function after transplantation
105. Technique failure in peritoneal dialysis and its impact on patient survival
106. ESRD modality selection into the 21st century: The importance of nonmedical factors
107. Multicenter study on patient referral to dialysis
108. The referral pattern of patients with ESRD is a determinant in the choice of dialysis modality
109. Peritoneal sclerosis in chronic peritoneal dialysis patients: Analysis of clinical presentation, risk factors and peritoneal transport kinetics
110. Improvement of transcellular water transport by treatment with glucose free dialysate in patients with ultrafiltration failure
111. Ultrafiltration with an isosmotic solution during long peritoneal dialysis exchanges
112. A randomised multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose in CAPD
113. Glycation and advanced end-product formation with icodextrin and dextrose
114. Icodextrin 7.5% dialysate solution (glucose polymer) in patients with ultrafiltration failure: Extension of CAPD technique survival
115. Icodextrin instead of glucose during the long daytime dwell in CCPD patients increases ultrafiltration and 24-h dialy-sate creatinine clearance
116. Comparison of icodextrin and glucose solutions for the daytime dwell in automated peritoneal dialysis
117. Effect of icodextrin use on total and LDL cholesterol in hypercholesterolemic PD patients
118. Future clinical research with icodextrin-containing solutions
119. Icodextrin hypersensitivity in a CAPD patient
120. Clinical experience with a 39 mmol/l bicarbonate-buffered peritoneal dialysis solution
121. A randomised controlled trial of a bicarbonate- and bicarbonate/lactate-containing peritoneal dialysis solution
122. A controlled trial of two bicarbonate-containing fluids for CAPD - Final report
123. Treatment of infusion pain by bicarbonate and bicarbonate/lactate containing PD solutions
124. Treatment of malnourished CAPD patients with an amino acid based dialysate
125. Clinical evaluation of an optimised 1.1% amino acid solution for peritoneal dialysis
126. Treatment of malnutrition with 1.1% amino acid peritoneal dialysis solution: Results of a multicentre outpatient study
127. Six-month overnight intraperitoneal amino acid infusion on CAPD patients: No effect on nutritional status
128. Fasting plasma amino acids are not normalised by 12-month amino-acid-based dialysate in CAPD patients
129. Clinical and physiological effects of a new, less toxic and less acidic solution for peritoneal dialysis
130. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products
131. Less infusion pain and elevated levels of cancer antigen 125 by the use of a new and more biocompatible PD fluid
132. Reduced glucose degradation products in bicarbonate/lactate-buffered peritoneal dialysis solutions produced in two-chambered bags
133. Conventional and newer peritoneal dialysis solutions
134. Strategies to reduce glucose exposure in peritoneal dialysis patients
135. Peritoneal dialysis solutions for the 21st century
136. Innovative peritoneal dialysis: Flow-thru and dialysate regeneration
137. Future developments in the treatment of endstage renal disease: A North American perspective
138. Dialysis: A five-year perspective
139. The potential of gene therapy in the peritoneal cavity
140. Mesothelial cell mediated gene therapy. Feasibility of an ex vivo strategy
141. Healthcare systems - An international review: An overview
142. The cost of caring for end-stage kidney disease patients: An analysis based on hospital financial transactions
143. Impact of capitation on free standing dialysis facilities: Can you survive?
144. Outcomes in peritoneal dialysis and haemodialysis - A comparative assessment of survival and quality of life
145. Peritoneal dialysis
146. Healthcare systems and ESRD therapies - An international review: Access to ESRD therapy
147. Health-care economics and peritoneal dialysis
148. A multi-centre, selection adjusted comparison of patient and technique survivals on CAPD and hemodialysis
149. Ten years experience with CAPD
150. Long term outcome in CAPD: A 10 year survey by the Italian Co-operative Peritoneal Dialysis Study Group
151. Issues affecting the longevity of the continuous peritoneal dialysis therapy